article thumbnail

PureTech Reveals New CBD Pill to Rival Jazz’s Epidiolex

XTalks

Clinical-stage biotech company PureTech Health has announced it has developed a new oral CBD therapeutic candidate with improved bioavailability and tolerability, which could expand use of the CBD prodrug in a wide range of indications and age groups. Epidiolex contains sesame seed oil, restricting its use for some individuals.

article thumbnail

Compliance to convenience: understanding the latest innovations in capsule formulation

Pharmaceutical Technology

Softgel capsules, containing a liquid, paste or emulsion active ingredient, are trusted and favoured by many patients. They also offer enhanced bioavailability, exact dosing and an extended shelf life. Softgels have now achieved strong recognition in the prescription, consumer health and supplements markets.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

EverGrain’s Line of Barley-Based Products Scores Upcycled Certification

XTalks

In terms of its nutritional profile, EverPro is high in bioavailable protein, low in carbohydrates, contains just half a gram of sugar per 100 grams and is free from cholesterol, dairy and soy. Both Bright Barley and EverGrain are tapping into the massive global barley market, which is estimated to reach $24.7

article thumbnail

Nanoform sets a new near-term business target for 2021

The Pharma Data

The information in the press release is information that Nanoform is obliged to make public pursuant to the EU Market Abuse Regulation. Nanoform’s shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). . +46 7686 650 11. 2 Proof of Concept.

article thumbnail

Calliditas Announces Full Enrollment of the Phase 3 NefIgArd Trial

The Pharma Data

Part B is designed to be a confirmatory post-market approval observational trial to confirm long-term renal protection and assess the difference in kidney function between treated and placebo patients as measured by eGFR over a two-year period from the start of dosing of each patient. It also showed that Nefecon was generally well-tolerated.

Trials 52
article thumbnail

Nanoform launches technology for biologics and sets new near-term business target for 2021

The Pharma Data

This novel nanoparticle formation technology provides hope for improving the possibilities and probabilities of developing better medicines for patients and it expands Nanoform’s reach into the growing biological market. Finnish time. About Nanoform. Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 562 1806.

article thumbnail

Kura Oncology Announces Pricing of $300 Million Public Offering of Common Stock

The Pharma Data

Kura’s most advanced drug candidate is tipifarnib, a potent, selective and orally bioavailable farnesyl transferase inhibitor currently in a registration-directed trial (AIM-HN) in patients with recurrent or metastatic HRAS mutant head and neck squamous cell carcinoma. Forward-Looking Statements.